Equity and Ethics
Equity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.
What is Equity and Ethics?
The field of psychedelics has faced significant ethical concerns, particularly regarding the representation and inclusion of diverse populations in clinical trials. Historical biases, such as the WEIRD bias, lead to a predominance of participants from Western, educated, industrialised, rich, and democratic backgrounds, undermining the generalisability of findings across different ethnic and cultural groups.
Indigenous communities, who have utilised these substances for centuries, are at risk of being excluded from the benefits of their cultural heritage as commercialization trends gain momentum. This further complicates the landscape, as modern psychedelic research often adapts traditional practices to fit Western medicine.
The legacy of the War on Drugs creates a psychological reluctance among racial minorities, particularly African Americans, to engage with psychedelic-assisted therapies. Addressing these issues is crucial to ensuring equitable access and reducing health disparities associated with mental health treatments.
Current Treatments
Standard treatments for mental health disorders include pharmaceuticals (e.g., SSRIs, SNRIs) and psychotherapy. However, psychedelic-assisted therapy is emerging as a potential alternative, poised to offer novel approaches alongside traditional treatments.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Equity and Ethics.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Ongoing trials show consistent therapeutic benefits in controlled studies, although evidence is still emerging. | Medium | Moderate | Consistent |
| MDMA MDMA-assisted therapy has undergone rigorous trials demonstrating significant efficacy in treating PTSD. | Large | High | Highly Consistent |
| Ayahuasca Research varies widely, with some studies showing potential benefits while others lack robust methodologies. | Medium | Moderate | Inconsistent |
| Ketamine Widely studied for its rapid antidepressant effects in treatment-resistant depression. | Large | High | Consistent |
Psilocybin and Equity and Ethics
Psilocybin is thought to facilitate profound psychological and emotional experiences that help alleviate anxiety and depression. Its efficacy in clinical trials for therapeutic use demonstrates its potential to assist individuals in processing traumatic memories and cultivating a renewed perspective on their mental health issues.
MDMA and Equity and Ethics
MDMA's unique mechanism of action enhances emotional connectivity and empathy, making it especially effective in psychotherapy for trauma. It is frequently administered in a therapeutic setting to facilitate discussions about past traumas and promote healing through interpersonal connection.
Ayahuasca and Equity and Ethics
Ayahuasca, traditionally used within Indigenous practices, induces vivid introspective experiences that can lead to significant psychological insights. While some evidence suggests its therapeutic potential in treating mood disorders, more rigorous research is needed to understand its mechanisms and ensure safe application within therapeutic contexts.
Ketamine and Equity and Ethics
Ketamine is increasingly recognised for its rapid antidepressant effects, particularly in treatment-resistant depression. Its ability to induce altered states of consciousness may provide novel pathways for addressing psychological distress and facilitating therapeutic breakthroughs.
Key Insights
- 1
The inequities in clinical trial participation limit the understanding of how diverse populations respond to psychedelic therapies.
- 2
Initiatives like the Indigenous Reciprocity Initiative aim to ensure that Indigenous voices are integral to the psychedelic discourse and benefit-sharing.
- 3
The current designation of psychedelics as Schedule I substances poses barriers to research and increases costs, limiting their potential as accessible treatments.
- 4
Collaborative efforts between companies and Indigenous groups are essential for preserving traditional knowledge and ensuring fair profits from psychedelics.
- 5
Adopting an Open Science approach could facilitate wider access to psychedelic therapies by sharing knowledge and methodologies openly.
Industrial Landscape
Key organisations include the Chacruna Institute, Woven Science, Journey Colab, and the Indigenous Medicine Conservation Fund, all of which focus on upholding Indigenous rights and promoting equity in psychedelic therapy.
Quick Indicators
\"Ongoing clinical evaluations are investigating Equity and Ethics as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Equity and Ethics.